Assenagon Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.77M | Buy |
17,686
+11,281
| +176% | +$3.68M | 0.01% | 526 |
|
|
2025
Q1 | $1.73M | Sell |
6,405
-13,513
| -68% | -$3.65M | ﹤0.01% | 776 |
|
|
2024
Q4 | $4.69M | Buy |
19,918
+2,285
| +13% | +$538K | 0.01% | 682 |
|
|
2024
Q3 | $4.85M | Sell |
17,633
-105,163
| -86% | -$28.9M | 0.01% | 704 |
|
|
2024
Q2 | $29.8M | Buy |
122,796
+62,454
| +104% | +$15.2M | 0.07% | 199 |
|
|
2024
Q1 | $9.02M | Buy |
60,342
+46,176
| +326% | +$6.9M | 0.02% | 435 |
|
|
2023
Q4 | $2.71M | Buy |
14,166
+7,436
| +110% | +$1.42M | 0.01% | 795 |
|
|
2023
Q3 | $1.19M | Sell |
6,730
-84,132
| -93% | -$14.9M | ﹤0.01% | 978 |
|
|
2023
Q2 | $17.3M | Sell |
90,862
-124,329
| -58% | -$23.6M | 0.06% | 235 |
|
|
2023
Q1 | $43.1M | Buy |
215,191
+207,364
| +2,649% | +$41.5M | 0.15% | 111 |
|
|
2022
Q4 | $1.86M | Buy |
7,827
+1,569
| +25% | +$373K | 0.01% | 805 |
|
|
2022
Q3 | $1.25M | Buy |
+6,258
| New | +$1.25M | ﹤0.01% | 850 |
|
|
2022
Q1 | – | Sell |
-174,443
| Closed | -$29.6M | – | 1358 |
|
|
2021
Q4 | $29.6M | Sell |
174,443
-159,846
| -48% | -$27.1M | 0.09% | 140 |
|
|
2021
Q3 | $63.1M | Buy |
334,289
+50,489
| +18% | +$9.53M | 0.2% | 74 |
|
|
2021
Q2 | $48.1M | Buy |
283,800
+160,032
| +129% | +$27.1M | 0.16% | 89 |
|
|
2021
Q1 | $17.5M | Buy |
123,768
+101,135
| +447% | +$14.3M | 0.07% | 207 |
|
|
2020
Q4 | $2.94M | Sell |
22,633
-20,552
| -48% | -$2.67M | 0.01% | 411 |
|
|
2020
Q3 | $6.29M | Sell |
43,185
-75,334
| -64% | -$11M | 0.04% | 246 |
|
|
2020
Q2 | $17.6M | Buy |
118,519
+94,607
| +396% | +$14M | 0.11% | 101 |
|
|
2020
Q1 | $2.6M | Buy |
+23,912
| New | +$2.6M | 0.02% | 280 |
|
|
2019
Q4 | – | Sell |
-27,286
| Closed | -$2.19M | – | 709 |
|
|
2019
Q3 | $2.19M | Buy |
+27,286
| New | +$2.19M | 0.01% | 352 |
|